γδ T cells in humans and mice share many properties with lymphocytes from the innate immune system, expressing, for instance, activatory natural killer (NK)-cell receptors such as NKG2D, inhibitory KIR receptors, as well as other cytotoxic surface molecules such as tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). Like conventional αβ T lymphocytes, γδ T cells express rearranged T-cell receptor (TCRs) comprising two (one γ and one δ) chains, which -compared with rearranged and MHCrestricted αβ TCRs-have a limited range of MHC-unrestricted antigenic specificities. Of note, and again in common with NK cells, γδ T cells can express Fcγ receptors, most notably FcγRIII (CD16), which (at least in humans) is expressed to the highest levels by activated cells. 1 A relatively new theme in the research field dealing with human γδ T lymphocytes has emerged following the seminal observation that, upon activation by γδ TCR ligation, γδ T cells become capable of taking up antigens and mediate professional antigen presentation to When compared with mature human dendritic cells, γδ T lymphocytes express equivalent levels of costimulatory molecules and CCR7, and are equally potent at promoting proliferative responses in αβ T cells. 2 We initially hypothesized that the surface expression of CD16 by γδ T cells might be indicative of a phagocytic function, and we showed that human blood γδ T cells are indeed capable of taking up bacteria and beads, yet only upon target opsonisation by IgGs. Following the phagocytosis of beads coated with an influenza antigen, γδ T cells processed and presented the antigen to MHC Class II-restricted hybridoma T cells. 4 We therefore wondered whether there might be a link between the recognition of antibody-coated target cells and the professional antigen presentation that had previously been reported by Moser and coworkers, 2, 3, 5 and whether this might have implications for oncology, a field in which harnessing and regulating the function of professional antigen presenting cells (APCs) might be exploited therapeutically.
A precedent for this type of regulation is provided by dendritic cells (DCs), for which licensing upon the interaction with CD40 ligand (CD40L)-expressing helper T lymphocytes in the T-cell areas of draining lymph nodes is required for the presentation of antigens taken up by immature DCs at a site of injury, infection or cancer. [6] [7] [8] Interestingly, in the absence of a antibody-coated target cells, γδ T cells were capable of low levels of cross-presentation to MHC Class I-restricted αβ T cells. Conversely, the presence of opsonized target cells was sufficient to achieve a degree of cross-presentation by isoprenyl pyrophosphate (IPP)-activated human circulating γδ T cells that was equivalent to that of mature DCs. 9 We have termed this phenomenon "licensing" for professional APC function by γδ T cells. Strikingly, neither antibodies alone, target cells alone, nor target cells in the presence of non-binding antibodies are capable of eliciting this "licensed" state. We demonstrated licensing using both rituximab and CH14.18, two humanized IgG 1 antibodies targeting CD20 and the GD2 ganglioside, Following activation, γδ t cells display many properties of lymphocytes from the innate immune system, yet how they mediate antigen presentation remains an open conundrum. In humans, circulating γδ t cells that express the Vγ9Vδ2 t-cell receptor become reversibly licensed for professional antigen presentation only upon interaction with a target cell opsonized with IgGs.
evolution of adaptive immune responses, to perform two specialized functions (i.e., killing and antigen presentation) in a highly regulated manner. Our findings are perhaps most exciting from a therapeutic perspective, as they imply that monoclonal antibodies used in anticancer therapy might be combined with γδ T cells or γδ T-cell stimulating factors to modulate innate effector functions as well as the generation of secondary immune responses. ability to cross-present antigen is lost over a 24 h period. Strikingly, however, a licensed and then unlicensed γδ T cell can be "re-licensed" by the same antibody-opsonized target. We have recently observed that the "de-licensing" process is associated with the downregulation of the co-stimulatory molecules CD80 and CD86, while "re-licensing" is associated with their re-expression (unpublished observations).
Many aspects of the regulation of the APC function of γδ T cells remain to be investigated. For example, from a signal transduction perspective, it will be interesting to determine whether CD16 interacts with the γδ TCR at the synapse between γδ T cells and target cells and whether the rapid and reversible changes in co-stimulatory molecule expression are driven by cytokine secretion or reflect direct transcriptional effects. The APC function of γδ T cells from different anatomical sites and bearing different TCRs (that exhibit distinct ligand specificities) warrants detailed investigation. From an even more fundamental research-oriented perspective, it will be important to understand whether γδ T cells represent an evolutionarily primitive type of lymphocyte or rather one that has emerged after the respectively, which are clinically used for the treatment of B-cell malignancies and neuroblastoma. Human IgG 1 antibodies efficiently bind FcγRIII (CD16) and, accordingly, licensing was abrogated by CD16 blocking antibodies. 9 A model is therefore emerging suggesting that human γδ T cells are capable of operating as professional APCs similar to DCs and that-like DC-a specific licensing signal is required for them to acquire full-blown APC functions (Fig. 1) . We have also observed that, for acting as professional APCs, γδ T cells require the engagement of their TCR as well as a correct cytokine milieu, as demonstrated by the fact that γδ T cells acquired APC functions only in media conditioned by B-cell lymphoblastoid lines (B-LCLs). Indeed, we observed the aggregation of the γδ TCR in an immune complex at the sites of interaction between γδ T cells and rituximab-opsonized Daudi cells. 9 It will be interesting to determine the involvement of CD16-Fc interactions in this complex.
Unlike DCs, the licensing of γδ T cells is a reversible process. On separating licensed circulating γδ T cells from opsonized target cells and culturing them in the presence of IPP, we found that their 
